NCT04932824View on ClinicalTrials.gov

Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.

PHASE1CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

November 10, 2021

Study Completion Date

December 16, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

SCB-2019

a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.

Trial Locations (1)

Unknown

Linear Clinical Research, Nedlands

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY